Kids armed with anti-coronavirus B cells
It remains unclear whether B cell repertoires against coronaviruses and other pathogens differ between adults and children and how important these distinctions are. Yang
et al. analyzed blood samples from young children and adults, as well as tissues from deceased organ donors, characterizing the B cell receptor (BCR) repertoires specific to six common pathogens and two viruses that they had not seen before: Ebola virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Children had higher frequencies of B cells with convergent BCR heavy chains against previously encountered pathogens and higher frequencies of class-switched convergent B cell clones against SARS-CoV-2 and related coronaviruses. These findings suggest that encounters with coronaviruses in early life may produce cross-reactive memory B cell populations that contribute to divergent COVID-19 susceptibilities.
Search jobs 11-May-2021 CORRECTING and REPLACING Former FDA and NIH Leader Dr. Vicki Seyfert-Margolis Joins Penrose TherapeuTx Scientific Advisory Board
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science
ANN ARBOR, Mich. & CHICAGO (BUSINESS WIRE) Please replace the release with the following corrected version due to multiple revisions in the first and third paragraphs, as well as correcting all instances of MyOwnMed to My Own Med, Inc. in the release text and image caption.
The corrected release reads:
FORMER FDA AND NIH LEADER DR. VICKI SEYFERT-MARGOLIS JOINS PENROSE THERAPEUTX SCIENTIFIC ADVISORY BOARD
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science
Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins
A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The laboratory-created monoclonal antibody, called IC14, binds to a human protein, CD14, that is found on the surface of immune cells circulating in the blood and airway fluid and that also circulates as a stand-alone protein. CD14 helps immune cells recognize pathogens and injured or dying cells, alerting the immune system to danger and prompting it to respond.
NIH begins trial of antibody for Covid-19 linked respiratory disease 14th April 2021 (Last Updated April 14th, 2021 12:37)
The National Institutes of Health (NIH) has initiated a Phase II clinical trial of an investigational monoclonal antibody IC14 for treating hospitalised Covid-19 patients with respiratory disease and low blood oxygen.
Share Article
Colourised scanning electron micrograph of a cell (pink) infected with SARS-CoV-2 virus particles (teal), isolated from a patient sample. Credit: NIAID.
The National Institutes of Health (NIH) has initiated a Phase II clinical trial of an investigational monoclonal antibody IC14 for treating hospitalised Covid-19 patients with respiratory disease and low blood oxygen.
Share this article
Share this article
SEATTLE, April 13, 2021 /PRNewswire/ The Benaroya Research Institute at Virginia Mason (BRI) has, for the second time, been awarded the Immune Tolerance Network grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to lead the Immune Tolerance Network (ITN). This 7-year award supports the work of the ITN in cutting-edge clinical trials that, in conjunction with laboratory studies of immunological responses, are designed to uncover and target immune system checkpoints that have the ability to reverse autoimmune diseases and allergies and facilitate organ transplantation.